Example: air traffic controller
GeneSight Psychotropic
asenapine (Saphris®) cariprazine (Vraylar®) lumateperone (Caplyta®) lurasidone (Latuda®) paliperidone (Invega®) thiothixene (Navane®) ziprasidone (Geodon®) fluphenazine (Prolixin®) 1 olanzapine (Zyprexa ®) 1 quetiapine (Seroquel ®) 1 clozapine (Clozaril®) ®1,8 haloperidol (Haldol®) 1,8 chlorpromazine (Thorazine®) 1,6 aripiprazole ...
Tags:
Information
Domain:
Source:
Link to this page:
Documents from same domain
How to order the GeneSight test
genesight.comGeneSight@ Psychotropic COMBINATORIAL PHARMACOGENOMIC TEST Patient, Sample DOB: 7/22/1984 Order Number: 219 R.genesight Questions about report interpretation? Contact our Medical Information team 855.891.9415 medinfo@assurexhealth.com SIGNIFICANT GENE-DRUG INTERACTION ANTIDEPRESSANTS MODERATE GENE-DRUG INTERACTION …
Related documents
QUICK REFERENCE TO PSYCHOTROPIC MEDICATIONS
psyd-fx.comasenapine Saphris 10-20 mg low low + + 1-2 mg lurasidone Latuda 40-80 mg mid mid + + 10 mg aripiprazole Abilify 15-30mg low low + + 2 mg Consumer’s Guide to Psychiatric Drugs (2009) Preston, O’Neal, Talaga Child and Adolescent Psychopharmacology Made Simple (2010) Preston, O’Neal, Talaga 1Usual daily oral dosage
QUICK REFERENCE TO PSYCHOTROPIC MEDICATIONS
www.continuingedcourses.netasenapine Saphris 10-20 mg low low + + 1-2 mg lurasidone Latuda 40-80 mg mid mid + + 10 mg aripiprazole Abilify 15-30mg low low + + 2 mg Consumer’s Guide to Psychiatric Drugs (2009) Preston, O’Neal, Talaga Child and Adolescent Psychopharmacology Made Simple (2010) Preston, O’Neal, Talaga 1Usual daily oral dosage
DOSING AND TITRATION OF COMMONLY USED …
media.empr.comSaphris (asenapine SL tabs) Schizophrenia Acute: 5mg twice daily Maintenance: 5mg twice daily Acute: 5mg twice daily; max 20mg/day Maintenance: 10mg twice daily; max 20mg/day Maintenance: Increase to max 10mg twice daily after 1 week Seroquel (quetiapine fumarate tabs) Schizophrenia 25mg twice daily on day 1; increase by 25–50mg 2–3
Medications To Be Avoided Or Used With Caution in ...
www.apdaparkinson.orgSaphris® Block dopamine receptors, but dissociate from the recep-tor more quickly than typical antipsychotics. They also tend to block serotonin receptors in addition to dopamine recep-tors. The result is less parkin-sonism than that caused by the typical antipsychotics. Antiemetics (used to treat nausea or vomiting) Chlorpromazine Droperidol
LIST OF DIFFERENT GROUPS OF MEDICATIONS
www.cse.msu.edu(Saphris) is a 5 ‐HT2A and D2receptor antagonist under development for the treatment of schizophrenia and acute mania associated with bipolar disorder. • Paliperidone (Invega) ‐ Derivative of risperidone that was approved in 2006. • Iloperidone (Fanapt) ‐ Approved by the FDA
Aging Brain Care - UCLA GWEP
gwep.med.ucla.eduAsenapine Saphris™ Atenolol Tenormin™ Bupropion Wellbutrin™, Zyban™ Captopril Capoten™ Cetirizine Zyrtec™ Chlorthalidone Diuril™, Hygroton™ Cimetidine Tagamet™ Clidinium Librax™ Clorazepate Tranxene™ Codeine Contin™ Colchicine Colcrys™ Desloratadine Clarinex™ Diazepam Valium™ Digoxin Lanoxin™ Dipyridamole ...
Information Sheet for Psychotropic Medications
guardianadlitem.orgSep 04, 2015 · o Saphris (Asenapine) o Latuda (Lurasidone) * Abilify, Seroquel, and lozapine come with “lack ox Warnings” by the Food and Drug Administration . This means the medication can cause serious undesirable effects (such as a fatal, life-threatening or permanently disabling adverse reaction) to the potential benefit from the drug;
Medications Approved by the FDA for Bipolar Disorder
www.dbsalliance.orgMedication Brand Name Common side effects May interact with Aripiprazole Abilify® Insomnia Nausea Restlessness Tiredness Antidepressants such as Prozac or Paxil
Minimum Laboratory Monitoring For Psychotropic Medications
www.azcompletehealth.comWhite Blood Cell Count (WBC) w/ Absolute Neutrophil Count (ANC) Weekly for 1 st 6 months (if values within normal limits), then every 2 wks. for
Second Generation Antipsychotic Sheet
www.magellanprovider.com3—©2014‐2017 Magellan Health, Inc. v Leucht S., Komossa K, Rummel-Kluge C, et al. (2009). Meta-Analysis of Head-to Head Comparisons of Second Generation Antipsychotics in the Treatment of Schizophrenia.